Varicella-zoster virus peptide-Human Leukocyte Antigen complex (VZV peptide-HLA complex)

Varicella-zoster virus (VZV) peptide-HLA complexes are molecular assemblies consisting of a viral peptide fragment bound within the groove of a Human Leukocyte Antigen (HLA) molecule. These complexes are displayed on the surface of infected cells or professional antigen-presenting cells to be recognized by the T-cell receptors (TCRs) of CD4+ and CD8+ T lymphocytes. This recognition is a critical step in the adaptive immune response, leading to the destruction of infected cells and the establishment of long-term immunological memory. In the context of clinical medicine, these complexes are the primary targets for VZV vaccines, which aim to elicit a robust T-cell response to prevent shingles (herpes zoster) and its complications. Understanding the specific VZV peptides that form stable complexes with various HLA alleles is essential for the development of next-generation immunotherapies and diagnostic tools, such as MHC tetramers used to monitor VZV-specific immunity.

Other names

VZV pMHCVaricella-zoster virus peptide-MHC complexVZV-specific HLA-peptide complexVZV antigen-HLA complex

Vaccines containing VZV antigens (like glycoprotein E) are processed by antigen-presenting cells and presented as VZV peptide-HLA complexes to CD4+ and CD8+ T cells, stimulating a memory immune response that prevents viral reactivation or primary infection.